Adaptimmune Therapeutics PLC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Adaptimmune Therapeutics PLC reported a significant net loss and reduced revenue for Q2 2025, driven by a major asset sale and subsequent workforce restructuring.
Adaptimmune Therapeutics reports Q1 2025 results, highlighting TECELRA's commercial launch but also raising concerns about its ability to continue as a going concern due to significant net losses and negative cash flows.
Adaptimmune Therapeutics announced its Q3 2024 results, marked by the launch of Tecelra, a strategic restructuring, and significant revenue from collaboration agreements.
Adaptimmune Therapeutics saw a significant increase in revenue in the second quarter of 2024, primarily due to a contract modification related to the termination of its collaboration with Genentech.
Adaptimmune Therapeutics reported its first quarter 2024 results, highlighting a decrease in revenue due to the termination of a collaboration agreement, while preparing for the commercial launch of afami-cel.